MDS-PAS Congress 2026 Session Evaluation

MDS-PAS Congress 2026 Session 1102 Evaluation Form
Plenary Session 1102

Novel Genetic Therapies for Movement Disorders

February 13, 2026

10:15 - 12:00
Learning Objectives:

1. Evaluate recent preclinical studies and clinical trial data for novel genetic therapies for Parkinson's disease
2. Evaluate recent preclinical studies and clinical trial data for novel genetic therapies for Huntington's disease
3. Evaluate recent preclinical studies and clinical trial data for novel genetic therapies for rare metabolic disorders
Session Evaluation
The session met its learning objectives

Strongly agreeAgreeDisagreeStrongly disagree
The content is relevant to my professional and / or scientific interests.

Strongly agreeAgreeDisagreeStrongly disagree
The quality of the education process (method of presentation and information provided) was satisfactory and appropriate.

Strongly agreeAgreeDisagreeStrongly disagree
The information provided will enhance my care of patients with Movement Disorders and / or advance my scientific understanding of Movement Disorders.

Strongly agreeAgreeDisagreeStrongly disagree
The overall session organization was satisfactory and appropriate.

Strongly agreeAgreeDisagreeStrongly disagree
I would recommend this session to a colleague.

Strongly agreeAgreeDisagreeStrongly disagree
Faculty Assessment
Matthew Farrer
This speaker was able to effectively communicate the content of their presentation

Strongly AgreeAgreeStrongly DisagreeDisagreeDid not attend
The information was presented without commercial bias. The speaker did not discuss a single branded commercial product or service.

Strongly AgreeAgreeStrongly DisagreeDisagreeDid not attend
Tiago Mestre
This speaker was able to effectively communicate the content of their presentation

Strongly AgreeAgreeStrongly DisagreeDisagreeDid not attend
The information was presented without commercial bias. The speaker did not discuss a single branded commercial product or service.

Strongly AgreeAgreeStrongly DisagreeDisagreeDid not attend
Jennifer Friedman
This speaker was able to effectively communicate the content of their presentation

Strongly AgreeAgreeStrongly DisagreeDisagreeDid not attend
The information was presented without commercial bias. The speaker did not discuss a single branded commercial product or service.

Strongly AgreeAgreeStrongly DisagreeDisagreeDid not attend
How would you improve this activity?
Please provide any additional comments
The following category best describes your current major professional activity (choose one):

Patient managementBasic Science researchClinical ResearchTeachingResident/PhD StudentUndergraduate StudentOther
My country:
Should be Empty:

MDS-PAS Congress 2026 Session 1102 Evaluation Form

Plenary Session 1102

Novel Genetic Therapies for Movement Disorders